


**Product Name** : FHT-2344  
**Cat. No.** : PC-20343  
**CAS No.** : 2468058-90-2  
**Molecular Formula** : C<sub>23</sub>H<sub>24</sub>N<sub>6</sub>O<sub>5</sub>S<sub>2</sub>  
**Molecular Weight** : 528.60  
**Target** : Bromodomain  
**Solubility** : 10 mM in DMSO



## Biological Activity

FHT-2344 (FHT2344) is a potent, selective inhibitor of SMARCA4 and SMARCA2 (**BRG1** and **BRM**) with IC<sub>50</sub> of 26 and 13 nM respectively, the ATPase component of the BAF complex.

FHT-2344 displays no activity against the closely related ATPase CHD4 (IC<sub>50</sub>>200 μM).

FHT-2344 elicits lineage-specific effects on chromatin accessibility in treated cancer cells, causes reduced occupancy of master disease-associated transcription factors in 92-1 UM cells.

FHT-2344 affects the proliferation of many cancer cell types, and elicits rapid effects on UM, hematological cancer, and other cell lines inhibits the master transcription factor, SOX10, and its downstream transcriptional program, impacting cell survival and lineage specification.

FHT-2344 elicits tumor regression, demonstrating therapeutic utility in UM and perhaps other transcription factor-driven cancers.

## References

Elena Battistello, et al. *Mol Cell*. 2023 Mar 15;S1097-2765(23)00153-3.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com